Showing results (51-60 of 67) with videos related to
Sort By:
Pageof 7
ESMO Open|June 5, 2025
Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trialL Collet, J-C Noël, X Catteau, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2012
Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patientsF Bertucci, P Finetti, H Roche, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2014
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialS Loi, S Michiels, R Salgado, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2017
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trialL Buisseret, S Pommey, B Allard, et al.Breast (Edinburgh, Scotland)|October 11, 2011
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial designW Eiermann, J Bergh, F Cardoso, et al.Oncogene|December 6, 2011
Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesionsC-R Pradeep, A Zeisel, W J Köstler, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2018
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trialM Ignatiadis, S Litière, F Rothe, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2016
Consensus on precision medicine for metastatic cancers: a report from the MAP conferenceC Swanton, J-C Soria, A Bardelli, et al.British Journal of Cancer|September 17, 2014
The AURORA initiative for metastatic breast cancerD Zardavas, M Maetens, A Irrthum, et al.Pageof 7